Application of the Human Amniotic Membrane as an Adjuvant Therapy for the Treatment of Hepatocellular Carcinoma
- 1 December 2023
- book chapter
- Published by Springer Nature
- p. 129-146
Abstract
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related morbidity and mortality worldwide. Current therapeutic approaches suffer significant side effects and lack of clear understanding of their molecular targets. Recent studies reported the anticancer effects, immunomodulatory properties, and antiangiogenic effects of the human amniotic membrane (hAM). hAM is a transparent protective membrane that surrounds the fetus. Preclinical studies showed pro-apoptotic and antiproliferative properties of hAM treatment on cancer cells. Herein, we present the latest findings of the application of the hAM in combating HCC tumorigenesis and the underlying molecular pathogenies and the role of transforming growth factor-beta (TGFβ), P53, WNT/beta-catenin, and PI3K/AKT pathways. The emerging clinical applications of hAM in cancer therapy provide evidence for its diverse and unique features and suitability for the management of a wide range of pathological conditions. Keywords Adjuvant therapies Amniotic membrane Hepatocellular carcinomaKeywords
This publication has 170 references indexed in Scilit:
- Applications of Amniotic Membrane and Fluid in Stem Cell Biology and Regenerative MedicineStem Cells International, 2012
- Molecular Basis for the Regulation of Angiogenesis by Thrombospondin-1 and -2Cold Spring Harbor Perspectives in Medicine, 2012
- Management of Hepatocellular Carcinoma: An Update ΔσHepatology, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Control of Stem Cell Fate by Physical Interactions with the Extracellular MatrixCell Stem Cell, 2009
- Pivotal Role of mTOR Signaling in Hepatocellular CarcinomaGastroenterology, 2008
- Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinomaBritish Journal of Cancer, 2008
- Sutureless Amniotic Membrane Transplantation for Partial Limbal Stem Cell DeficiencyAmerican Journal of Ophthalmology, 2008
- Isolation of amniotic stem cell lines with potential for therapyNature Biotechnology, 2007
- Mdm2 promotes the rapid degradation of p53Nature, 1997